NCT05502185Unknown不适用
Targeting Staphylococci Adhesion and Colonization on the Surface of Corneocytes in Atopic Dermatitis
L'Oreal0 个研究点目标入组 60 人开始时间: 2022年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 60
- 主要终点
- Identification of S. epidermidis adhesins
研究概览
简要总结
The aim of the study is to deliver a better understanding of the molecular mechanisms used by S. epidermidis strains in their adhesion and colonization on the stratum corneum across a broad spectrum of atopic dermatitis in mild to moderate conditions in adult patients.
详细描述
Recent studies have shown that while in severe cases of AD the density of S. aureus is increased in lesions, the skin of adult patients with low to mild AD were overpopulated with S. epidermidis and not S. aureus.
the aim is to characterize the S. epidermidis colonization and adhesion, with the Analyzis of skin and microbiota samples to identify and characterize S. epidermidis strains involved in corneocytes adhesion.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •• Male/Female subject from 18 years old or above.
- •Subject willing and able to fulfil the study requirements and schedule
- •Subject informed about the study objectives and procedures, and able to understand them
- •Subject who has given written informed consent
- •Subject with I, II, III or IV skin phototype
- •Specific criteria:
- •For AD patients:
- •Subject diagnosed with AD (via UK working party criteria) with a mild-to-moderate severity defined as EASI<32 and vIGA between 2 and 3
- •Subject with at least one AD lesion covering at least 4 cm²
- •For healthy volunteers:
- •Subject matching the demographic characteristics of a patient included in the AD group: same sex, same phototype, same age (± 5 years)
排除标准
- •Subject with a body mass index (BMI) higher than 40
- •Presenting another dermatological condition that could interfere with the clinical evaluation
- •Presenting any concomitant medical condition that may interfere with the study conduct in the opinion of the investigator
- •Topical or systemic treatment that could interfere with the study treatment/assessments (topical benzoyl peroxide, salicylic acid and other anti-acne or antiseborrheic products, antibiotics, corticosteroids, retinoids, differin gel, retin-A, anti-inflammatory drugs, within the 4 weeks prior to the participation in the study.
- •Any physical treatment including laser or phototherapy (PUVA, IPL, PDT), topical fillers such as Botox on the investigational sites in the last 6 months and during the study
- •Subject treated with systemic non-steroidal anti-inflammatory drugs (≥3 days) within 1 week before the inclusion visit or intending to be treated with it during the study.
- •Subject treated with biological immunosuppressive drugs within 12 weeks prior to the inclusion visit or intending to be treated with it during the study.
- •Subject treated with non-biological immunosuppressive drugs within 4 weeks prior to the inclusion visit or intending to be treated with it during the study.
- •Subject treated with systemic corticoids within 1 week prior to the inclusion visit or planed during the study.
- •Subject treated with systemic antibiotics within 2 weeks prior to the inclusion visit or planned during the study.
- •Subject having applied topical corticosteroids and topical calcineurin inhibitors on the investigational areas within 1 week prior to the inclusion visit.
- •Subject having applied topical immunomodulators, non-steroidal anti-inflammatory, antihistamines on investigational area within 1 week prior to the inclusion visit.
- •Subject having applied topical antibiotics or disinfectants on investigational area within 2 weeks prior to the inclusion visit.
- •Subject having applied any other topical and/or care product within 12 hours of the visit.
- •Subject having applied water or care product (except hands cleaning) within 12 hours prior to the inclusion visit.
- •Subject having significant dermatological condition or sign (e.g disease, scare, abundant hairiness, tanning mark...) that according to the investigator's judgment, could limit the observations or/and interfere with the interpretations.
- •Subject having performed phototherapy within 8 weeks prior to the inclusion visit or intending to perform phototherapy during the study.
- •Subject having performed another physical treatment (e.g radiotherapy...) on the investigational areas within 6 months prior to the inclusion visit or intending to perform it during the study.
- •Subject having exposed their skin to natural or artificial UV within 2 weeks prior to the inclusion visit
- •Subject under legal guardianship or incapacitation.
- •Subject who declares to be deprived of freedom by administrative or legal decision
- •Subject linguistically or psychologically unable of signing informed consent form and unable to comply with the protocol requirements according to the investigator's judgment.
- •Subject who cannot be contacted by telephone in case of emergency.
- •Subject having participated within the 30 days before inclusion or currently participating in another clinical study.
结局指标
主要结局
Identification of S. epidermidis adhesins
时间窗: 1 week
Identification of S. epidermidis adhesins involved in corneocytes adhesion, in mild-to moderate AD conditions
次要结局
- characterization of corneocytes(1 week)
研究者
相似试验
已完成
不适用
Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections DevelopmentStaphylococcal InfectionNCT02812446Nantes University Hospital88
已完成
不适用
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)Methicillin-Resistant Staphylococcus AureusEczema HerpeticumMRSAAtopic DermatitisNCT00822276National Institute of Allergy and Infectious Diseases (NIAID)65
已完成
不适用
Virulence of Staphylococcus Lugdunensis in Severe InfectionsStaphylococcus LugdunensisVirulence FactorsEndocarditisBacteremiaNCT02026895University Hospital, Strasbourg, France82
已完成
不适用
Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University HospitalsStaphylococcus AureusNCT06291181Sohag University265
招募中
不适用
Molecular characterization of staphylococcal adaptation during asymptomatic colonization and infection.L20Atopic dermatitisDRKS00031078niklinik RWTH Aachen - Klinik für Dermatologie und Allergologie - Hautklinik15